Literature DB >> 3805727

Cytostatic and cytolytic effects of human recombinant tumor necrosis factor on human renal cell carcinoma cell lines derived from a single surgical specimen.

R Heicappell, S Naito, Y Ichinose, A A Creasey, L S Lin, I J Fidler.   

Abstract

The purpose of this study was to determine whether human tumor cell lines derived from a single tumor exhibit heterogeneous responses to the anti-tumor effects of human recombinant tumor necrosis factor (h-r-TNF). Several cell lines with different metastatic propensities have been established in culture from a single surgical specimen of a human renal cell carcinoma following different selection procedures in nude mice. The cell lines exhibited significant differences in in vitro susceptibilities to cytotoxic effects of TNF. Kinetic analysis of the interaction of TNF with susceptible renal carcinoma cells demonstrated that a short 30 min interaction of TNF with the cells is sufficient to produce significant lysis 72 hr later. One cycle of exposure of sensitive cells to h-r-TNF did not produce cells resistant to it, nor did the degree of sensitivity to h-r-TNF vary after one passage of the cells in nude mice. Tumor cell resistance to the effects of TNF did develop spontaneously after prolonged cultivation in culture. We conclude that tumor cells derived from a single human renal cell carcinoma exhibit a heterogeneous response to the cytotoxic effects of h-r-TNF.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3805727

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

1.  Effects of high-energy shock waves combined with biological response modifiers or Adriamycin on a human kidney cancer xenograft.

Authors:  G O Oosterhof; G A Smiths; J E deRuyter; J A Schalken; F M Debruyne
Journal:  Urol Res       Date:  1990

Review 2.  Rationale for immunotherapy of renal cell carcinoma.

Authors:  R Heicappell; R Ackermann
Journal:  Urol Res       Date:  1990

3.  Regulation of the expression of aminopeptidase A, aminopeptidase N/CD13 and dipeptidylpeptidase IV/CD26 in renal carcinoma cells and renal tubular epithelial cells by cytokines and cAMP-increasing mediators.

Authors:  A Kehlen; B Göhring; J Langner; D Riemann
Journal:  Clin Exp Immunol       Date:  1998-02       Impact factor: 4.330

4.  Enhanced in vivo cytotoxicity of recombinant human tumor necrosis factor with etoposide in human renal cell carcinoma. Evaluation in a pre-clinical model.

Authors:  J T Donaldson; T E Keane; S H Poulton; P J Walther
Journal:  Urol Res       Date:  1990

5.  Cancer cell glycocalyx mediates mechanotransduction and flow-regulated invasion.

Authors:  Henry Qazi; Rocio Palomino; Zhong-Dong Shi; Lance L Munn; John M Tarbell
Journal:  Integr Biol (Camb)       Date:  2013-09-30       Impact factor: 2.192

6.  Destruction of tumor cells by monokines released from activated human blood monocytes: evidence for parallel and additive effects of IL-1 and TNF.

Authors:  Y Ichinose; J Y Tsao; I J Fidler
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

7.  Sensitivity of fresh and cultured ovarian tumor cells to tumor necrosis factor, interferon-alpha 2, and OK-432.

Authors:  Y Nio; J Zighelboim; J S Berek; B Bonavida
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

8.  Tumor necrosis factor and interleukin-1 activities in free lung cells after single and repeated inhalation of bacterial endotoxin.

Authors:  B de Rochemonteix-Galve; B Marchat-Amoruso; J M Dayer; R Rylander
Journal:  Infect Immun       Date:  1991-10       Impact factor: 3.441

9.  Comparative efficacy of liposomes containing synthetic bacterial cell wall analogues for tumoricidal activation of monocytes and macrophages.

Authors:  T Utsugi; A Nii; D Fan; C C Pak; Y Denkins; P van Hoogevest; I J Fidler
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

10.  Anti-tumor action of tumor necrosis factor against Bomirski Ab melanoma in hamsters.

Authors:  Patrycja Koszałka; Ewa Szmit; Andrzej Myśliwski; Jacek Bigda
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2007-07-23       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.